North America

North America’s psychedelic field in 2026-Q2 is shaped by five cross-cutting dynamics that only become clear when the three countries are read together.

First, the region is splitting into an evidence hub and an access bottleneck. The United States still drives the largest share of regulated research infrastructure, with federated trial pathways, FDA oversight, and multiple state experiments creating a dense but fragmented pipeline. Canada is also active, especially in psilocybin-led research, but the country’s access model remains tightly medical and exceptional, with Special Access Programme routes and clinical trials doing most of the work. Mexico, by contrast, has a narrower formal research footprint for classical psychedelics and a more restrictive psychotropic framework. Read regionally, North America is producing more evidence than practical availability, and that mismatch is one of the defining features of the quarter.

Second, ketamine and esketamine continue to define the real clinical floor across the region. In the United States, ketamine is still a Schedule III medicine and esketamine is the only FDA-approved nasal psychedelic-adjacent antidepressant. Canada has meaningful real-world esketamine access, even if reimbursement and public-plan decisions remain uneven. Mexico’s public-system recognition of esketamine also matters, because it shows how the region’s most usable psychedelic-adjacent medicine is not a classic psychedelic at all, but a dissociative antidepressant already embedded in mainstream systems. This shared reliance on ketamine-class treatments is easy to miss if each country is viewed separately.

Third, the classical-psychedelic regulatory story is still mostly about controlled exceptions rather than general authorisation. Canada allows patient-specific access via the Special Access Programme, but that is not a general approval route. The United States remains anchored in federal Schedule I controls for psilocybin, MDMA, LSD and related compounds, even as state models in Oregon, Colorado, New Mexico and elsewhere create partial, localised pathways. Mexico’s Article 245 and Article 249 framework keeps psilocybin, MDMA, LSD, DMT and mescaline in the highest-control category, limiting acquisition to authorised scientific research. Regionally, that means the policy debate is not about whether psychedelics are “accepted”, but about which narrow legal corridor, if any, a given compound can move through.

Fourth, the region’s policy innovation is increasingly subnational in the United States, while Canada and Mexico remain more federal in their posture. Oregon’s live service model, Colorado’s licensing architecture, New Mexico’s programme build-out and research-led activity in Texas, Utah and Arizona mean the US is generating implementation lessons at the state level that have no direct analogue in Canada or Mexico. That creates a regional asymmetry: the US is simultaneously the least settled federal jurisdiction and the most experimentally diverse one. Canada and Mexico do not have that breadth of state-style variation, so their systems remain easier to describe but slower to evolve.

Fifth, the region is seeing a quiet convergence around depression, end-of-life distress, and treatment-resistant populations, but not around a single compound. Canada’s visible psilocybin pipeline spans end-of-life distress, treatment-resistant depression, obsessive-compulsive disorder, alcohol use disorder, chronic pain and post-concussion symptoms. The United States has the broadest set of academic and commercial programmes, including depression, cancer-related distress, addiction and mechanistic work. Mexico’s formal clinical footprint is narrower, but esketamine and ketamine keep it relevant to the same treatment-resistant psychiatric segment. This suggests that North America’s psychedelic field is no longer just about classical psychedelics in isolation, but about a broader neuropsychiatric toolkit where ketamine, esketamine, psilocybin and related compounds are competing for different parts of the same clinical need.

Over the next 12 to 24 months, North America is likely to see more movement in evidence generation than in headline-making legal change. In the United States, the most plausible developments are additional readouts and protocol refinement across psilocybin, LSD-derived programmes, ketamine/esketamine, and adjacent compounds, while state systems continue to test what regulated service delivery can actually look like. The federal picture is unlikely to shift quickly, so the main question is whether state models can produce durable implementation evidence without being mistaken for national reform.

Canada’s near-term path looks more incremental. The country is still well positioned to contribute clinically meaningful data, especially in depression, palliative care and pain, but the practical access route will probably remain narrow. The Special Access Programme and research exemptions can support selective cases, yet they do not amount to broad market access. That means the important Canadian question is not whether psilocybin becomes fully legal in routine care this year, but whether better evidence starts to change how regulators, hospitals and payers think about exceptional access.

Mexico is likely to remain the most restrictive of the three on classical psychedelics, while keeping ketamine and esketamine at the centre of formal psychiatric use. The near-term story there is operational rather than legislative, with research authorisations, institutional adoption and public-system procurement likely to matter more than statutory reform. Regionally, that means North America should be read less as a single liberalising bloc and more as a set of parallel systems, each advancing, but at different speeds and through different compounds.